Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 25, 2021 at 02:51 pm IST
Share
Nanjing Hicin Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 453.52 million compared to CNY 547.95 million a year ago. Revenue was CNY 453.52 million compared to CNY 547.95 million a year ago. Net income was CNY 28.23 million compared to CNY 48.34 million a year ago. Basic earnings per share from continuing operations was CNY 0.2353 compared to CNY 0.4028 a year ago. Diluted earnings per share from continuing operations was CNY 0.2353 compared to CNY 0.4028 a year ago.
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
NANJING HICIN PHARMACEUTICAL CO., LTD. 
